Veru Inc.

NASDAQ:VERU

Biotechnology

Healthcare
$3.16 +4.33%

+$0.13 today

Market cap
$50.72M
Beta
-1.13
P/E (TTM)
-4.8
EPS (TTM)
-$0.65
52W Low $2.05High $7.33

Volume 0.34M

Average 1.82M

VERU Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Veru Inc.NASDAQ: VERU

Revenue · Q2 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q2 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearSep 2025
$0-100.0% YoY
LTMMar 2026
$0-100.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How VERU compares with its peers on the latest reported figures

  • VERU's LTM Mar 2026 revenue of $0 is the 4th highest of the 7 companies compared; the peer median is $744.5K.
  • Its year-over-year change of -100.0% is the lowest of 4, against a peer median of -11.0%.
VERU Competitors Peer median
Revenue for VERU and competitors
Company Period LTM YoY 3-year CAGR
CELUCelularity Inc.LTM Dec 2025$26.55M -51.0%+13.9%
DYAIDyadic International, Inc.LTM Mar 2026$2.97M -11.0%-25.1%
RNXTRenovoRx, Inc.LTM Mar 2026$1.49M +520.4%—
VERUVeru Inc.LTM Mar 2026$0 -100.0%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 ——
PYPDPolyPid Ltd.LTM Mar 2026$0 ——
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 ——
Peer median (excluding VERU) $744.5K-11.0%-5.6%

Competitors are the stored peer set for VERU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue61.26M39.35M16.3M16.89M0
Cost of Revenue13.33M8.76M8.73M11.03M0
Gross Profit47.93M30.59M7.57M5.85M0
Gross Margin78.2%77.7%46.4%34.7%—
Research & Development32.69M70.65M51.2M12.81M15.59M
Selling, General & Admin20.67M43.17M48.06M31.18M19.94M
Operating Expenses53.36M113.81M101.35M42.77M24.75M
Depreciation & Amortization593.87K209.6K269.87K268.18K152.11K
EBITDA9.75M(79.23M)(89.98M)(36.2M)(35.38M)
EBITDA Margin15.9%-201.3%-552.1%-214.4%—
Operating Income12.97M(83.22M)(93.78M)(36.92M)(24.75M)
Operating Margin21.2%-211.5%-575.5%-218.6%—
Interest Income00000
Interest Expense4.89M4.37M2.43M607.47K0
Other Income / Expenses(8.71M)(580.66K)1.11M(160.93K)9.07M
Income Before Tax4.27M(83.8M)(92.67M)(37.08M)(15.68M)
Pre-Tax Margin7.0%-212.9%-568.6%-219.6%—
Income Tax Expense(3.13M)236.4K480.21K725.1K0
Net Income7.39M(83.78M)(93.15M)(37.8M)(22.73M)
Net Margin12.1%-212.9%-571.6%-223.9%—
EPS (Basic)0.97(10.49)(10.96)(2.80)(1.07)
EPS (Diluted)0.88(10.49)(10.96)(2.80)(1.07)
Weighted Avg Shares7.63M8.01M8.5M13.49M14.65M
Weighted Avg Shares (Diluted)8.38M8.01M8.5M13.49M14.65M

Veru Inc.

NASDAQ:VERU

Intrinsic Alpha fair value

Locked

Current Price

$3.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.